Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: Preliminary results from a phase 1b/2 study.

被引：0
|
作者：
Lee, Keun-Seok
Wang, Xiaojia
Im, Young Hyuck
Zeng, Xiaohua
Li, Huiping
Wang, Kun
Li, Huiyan
Zhou, Ping
Bao, Yuanyuan
Jiang, Zefei
机构：
[1] Natl Canc Ctr, Ctr Breast Canc, Goyang, South Korea
[2] Zhejiang Canc Hosp, Dept Oncol, Hangzhou, Peoples R China
[3] Sungkyunkwan Univ, Dept Oncol, Samsung Med Ctr, Sch Med, Seoul, South Korea
[4] Chongqing Univ Canc Hosp, Dept Breast Canc Ctr, Chongqing, Peoples R China
[5] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Dept Breast Oncol, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[6] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Breast Canc, Canc Ctr, Guangzhou, Peoples R China
[7] BeiGene Co Ltd, Shanghai, Peoples R China
[8] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1031
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study
    Wang, Xiaojia
    Lee, Keun Seok
    Zeng, Xiaohua
    Sun, Tao
    Im, Young-Hyuck
    Li, Huiping
    Wang, Kun
    Li, Huiyan
    Zhou, Ping
    Bao, Yuanyuan
    Jiang, Zefei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study.
    Lee, Keun Wook
    Bai, Li-Yuan
    Jung, Minkyu
    Ying, Jieer
    Im, Young Hyuck
    Oh, Do-Youn
    Cho, Jae Yong
    Oh, Sang Cheul
    Chao, Yee
    Li, Huiyan
    Zhou, Ping
    Bao, Yuanyuan
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study
    Bedard, Philippe L.
    Im, Seock-Ah
    Elimova, Elena
    Rha, Sun Young
    Goodwin, Rachel
    Ferrario, Cristiano
    Lee, Keun-Wook
    Hanna, Diana
    Meric-Bernstam, Funda
    Mayordomo, Jose
    Beeram, Murali
    Hamilton, Erika
    Chaves, Jorge
    Cobleigh, Melody
    Mwatha, Tony
    Woolery, Joseph
    Oh, Do-Youn
    CANCER RESEARCH, 2022, 82 (04)
  • [4] Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: Results from a phase 1b study
    Zhang, Qingyuan
    Wang, Jingxuan
    Li, Liru
    Zeng, Xiaohua
    Zhang, Han
    Song, Ying
    Tang, Dabei
    Niu, Xingjian
    Ma, Wenjie
    Tu, Lifan
    Fu, Shuang
    Pan, Zoucheng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Efficacy and safety results of KN026, a HER2-targeted bispecific antibody combined with docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer
    Zhang, Qingyuan
    Wang, Jingxuan
    Ouyang, Quchang
    Wang, Xiaojia
    Wang, Jingfen
    Gan, Lu
    Lin, Daren
    Ouyang, Zhong
    Xu, Ting
    Liu, Yilan
    Xia, Summer
    CANCER RESEARCH, 2023, 83 (05)
  • [6] Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study
    Lee, K-W.
    Bai, L-Y.
    Jung, M.
    Ying, J.
    Im, Y-H.
    Oh, D-Y.
    Cho, J. Y.
    Oh, S. C.
    Chao, Y.
    Zhou, P.
    Bao, Y.
    Kang, Y-K.
    ANNALS OF ONCOLOGY, 2023, 34 : S855 - S856
  • [7] Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
    Lee, Keun Wook
    Im, Young-Hyuck
    Lee, Keun Seok
    Cho, Jae Yong
    Oh, Do-Youn
    Chung, Hyun Cheol Cheol
    Chao, Yee
    Bai, Li-Yuan
    Yen, Chia Jui
    Kim, In-Ho
    Oh, Sang Cheul
    Lin, Chia-Chi
    Wang, Jin
    Wang, Xin
    Li, Huiyan
    Chen, Yen-Yang
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
    Zhang, Jian
    Ji, Dongmei
    Cai, Li
    Yao, Herui
    Yan, Min
    Wang, Xiaojia
    Shen, Weina
    Du, Yiqun
    Pang, Hui
    Lai, Xiuping
    Zeng, Huiai
    Huang, Jian
    Sun, Yan
    Peng, Xinxin
    Xu, Junfang
    Yang, Jing
    Yang, Fei
    Xu, Ting
    Hu, Xichun
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 618 - 628
  • [9] First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: Results from a phase I study
    Zhang, Jian
    Ji, Dongmei
    Cai, Li
    Yao, Herui
    Yan, Min
    Wang, Xiaojia
    Shen, Weina
    Du, Yiqun
    Pang, Hui
    Lai, Xiuping
    Zeng, Huiai
    Huang, Jian
    Sun, Yan
    Peng, Xinxin
    Xu, Junfang
    Yang, Jing
    Yang, Fei
    Xu, Ting
    Hu, Xichun
    CANCER RESEARCH, 2022, 82 (04)
  • [10] An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer
    Cardoso, Fatima
    Canon, Jean-Luc
    Amadori, Dino
    Aldrighetti, Daniela
    Machiels, Jean-Pascal
    Bouko, Yasmina
    Verkh, Lev
    Usari, Tiziana
    Kern, Kenneth A.
    Giorgetti, Carla
    Dirix, Luc
    BREAST, 2012, 21 (06): : 716 - 723
12345